Linda A.Hesse

Associée

Paris + 33.1.56.59.38.72

En charge de la pratique Droit boursier du bureau de Paris, Linda Hesse exerce dans le domaine du droit boursier, des marchés de capitaux et de la corporate governance depuis plus de vingt ans.

Linda Hesse agit en tant que conseil des sociétés, telles que Orange, Sanofi, EDAP et Stallergenes Greer, lors de leurs introductions en bourse à Paris ou aux Etats-Unis, leurs émissions de titres financiers et dans le cadre de leurs démarches auprès de l’AMF et de la SEC.

Elle est très régulièrement conseil dans le cadre d’OPA et de fusions de sociétés cotées (dont l'acquisition de Panalpina par DSV, de Technopolis Plc par Kildare Partners, l'acquisition des actionnaires minoritaires de Stallergenes Greer par Waypoint, de Zodiac Aerospace par Safran, la fusion de Stallergenes et Greer, l’offre de Wabtec pour Faiveley et les offres d’Essilor International pour FGX et Shamir Opticals) ainsi que plus généralement pour toutes questions relatives au droit boursier.

Linda Hesse conseille régulièrement les banques d’investissements, telles que BNP Paribas, Crédit Agricole CIB, Société Générale et Natixis lors d’opérations de marchés telles que l'introduction en bourse de Genfit sur le Nasdaq, Sequans sur la NYSE et Medincell sur Euronext Paris, et les augmentations de capital de Genfit, Rubis et Valneva.

Membre de l'International Bar Association (IBA), Linda Hesse est active au sein du Securities Law Committee.

Expérience

  • Berenberg, BNP Paribas, and TP ICAP Europe complete €87.3 million offering by Bigben Interactive of its inaugural senior conditionally secured bonds exchangeable into existing ordinary shares of NaconJones Day advised Berenberg, BNP Paribas, and TP ICAP Europe, as joint global coordinators and joint bookrunners, in connection with a €87.3 million offering by Bigben Interactive, a European player in video game development and publishing, in design and distribution of smartphone and gaming accessories as well as in audio products, of its inaugural senior conditionally secured bonds exchangeable into existing ordinary shares of Nacon due 2026.
  • Bryan, Garnier & Co Limited and ODDO BHF SCA complete €29.8 million capital increase of MedinCell S.A.Jones Day represented Bryan, Garnier & Co Limited (acting via Bryan Garnier Securities SAS) and ODDO BHF SCA, as joint global coordinators and joint bookrunners, in connection with the €29.8 million capital increase of MedinCell S.A., a clinical stage pharmaceutical company.
  • H.C. Wainwright underwrites Nasdaq IPO by Biophytis, including issuance of 1.2 million American Depositary SharesJones Day advised H.C. Wainwright, as underwriter, in connection with the Nasdaq IPO by Biophytis S.A., a French Euronext Growth-listed biotech company, including the issuance of 1.2 million American Depositary Shares (ADSs).
  • Voltalia issues inaugural green bondsJones Day represented Voltalia in connection with its inaugural green bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs Vertes) due 2025 for a nominal amount of approximately €200 million as well as within the implementation of its Green & Sustainability-linked Financing Framework.
  • Alchimie completes €17.9 million IPO of Ordinary SharesJones Day advised Alchimie SAS, a French OTT subscription video on demand platform, in connection with the €17.9 million initial public offering of Ordinary Shares listed on the multilateral trading facility of Euronext Growth Paris.
  • Bank Degroof Petercam SA/NV and Invest Securities complete €18.6 million private placement of shares by OSE Immunotherapeutics S.A.Jones Day represented Bank Degroof Petercam SA/NV and Invest Securities SA in connection with the €18.6 million private placement of shares by OSE Immunotherapeutics S.A., a French integrated biotechnology company developing innovative immunotherapies, directly or through partnerships, for immune activation and regulation in immuno-oncology and autoimmune diseases.
  • Bryan, Garnier & Co Limited and Chardan Capital Markets complete €25 million private placement of shares by GenSight Biologics S.A.Jones Day represented Bryan, Garnier & Co Limited and Chardan Capital Markets, LLC in connection with the €25 million private placement of shares by GenSight Biologics S.A., a French clinical-stage gene therapy company in the area of severe retinal neurodegenerative diseases.
  • Orocobre raises A$156 million by way of placement and share purchase planJones Day advised Orocobre Limited, a dual ASX and TSX-listed lithium chemicals producer, on a A$156 million capital raising by way of a fully underwritten placement to institutional investors of A$126 million and non-underwritten share purchase plan to shareholders in Australia and New Zealand of up to A$30 million.
  • Natixis, ODDO BHF SCA, and Bryan, Garnier & Co Limited complete €37 million private placement of shares by CarbiosJones Day represented Natixis, ODDO BHF SCA, and Bryan, Garnier & Co Limited, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the €37 million private placement of shares of Carbios, a French green chemistry company.
  • Oddo BHF SCA and Bryan, Garnier & Co Limited complete €15.6 million share capital increase of MedinCell S.A.Jones Day advised Oddo BHF SCA and Bryan, Garnier & Co Limited, as placement agents, in connection with the €15.6 million share capital increase of MedinCell S.A., a clinical stage pharmaceutical company.
  • Kalray receives €8 million investment from NXP Semiconductors N.V.Jones Day assisted Kalray, a pioneer in processors for new intelligent systems, in connection with the €8 million strategic investment from NXP Semiconductors N.V., enables companies to develop together safe, reliable, and scalable solutions for autonomous driving.
  • Largest Cineworld shareholder refinancesJones Day advised Global City Theatres B.V., (GCT), the largest shareholder of Cineworld Group plc (Cineworld), Regal in the U.S., as lead counsel on its debt refinancing and related capital market aspects.
  • Pharnext raises €7.7 million in private placementJones Day represented Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, in connection with its €7.7 million private placement of 1,799,061 of new Ordinary Shares.
  • Joh. Berenberg, Gossler & Co. KG; Gilbert Dupont; and Louis Capital Markets complete IPO of Ordinary Shares of Nacon S.A. on regulated market of Euronext in ParisJones Day advised Joh. Berenberg, Gossler & Co. KG; Gilbert Dupont; and Louis Capital Markets UK LLP in connection with the €100 million initial public offering of Ordinary Shares of Nacon S.A., a French company specialized in the development of video games and gaming accessories, on the regulated market of Euronext in Paris.
  • Selectirente completes €217 million capital increaseJones Day represented Selectirente S.A. in connection with the €217 million share capital increase without preferential subscription rights but priority subscription period granted to the existing shareholders.
  • Belfius Bank and Kempen complete €69 million placement of treasury shares by BefimmoJones Day assisted joint bookrunners Belfius Bank SA and Kempen & Co. in connection with the €69 million (US$75.5 million) placement of treasury shares by Befimmo SA, a REIT listed on Euronext Brussels, to qualified investors in Belgium, the European Economic Area, and to a limited number of qualified institutional buyers within the U.S.
  • Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc complete IPO of BoostheatJones Day advised Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the initial public offering of Boostheat SA, a designer, developer, and producer of technologically advanced, energy efficient, and sustainable heating solutions, on the regulated market of Euronext in Paris.
  • CARMAT completes €60 million reserved offering for specialized and strategic investorsJones Day advised CARMAT SA, a designer and developer of the world's most advanced heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, in connection with its €60 million (US$66.3 million) share capital increase, reserved for investors, specialists of the healthcare and life sciences industry, or strategic partners of CARMAT.
  • Panalpina and DSV join forces by way of CHF 4.6 billion (US$4.6 billion) public exchange of stockJones Day advised Panalpina Welttransport (Holding) AG, Basel, Switzerland, one of the world's leading freight forwarders, with respect to German, EU, and U.S. securities law aspects and foreign direct investment filings in connection with the combination with DSV A/S, Hedhusene, Denmark, by way of a CHF 4.6 billion (US$4.6 billion) public exchange offer of DSV to all Panalpina shareholders to tender their Panalpina shares (listed at SIX Swiss Exchange) against DSV shares (listed at NASDAQ Copenhagen).
  • Syndicate of leading banks complete €715 million share capital increase by Tikehau CapitalJones Day advised Berenberg, Credit Suisse, Natixis, BNP Paribas, Crédit Agricole Corporate and Investment Bank, and Société Générale, as global coordinators, joint lead managers and joint bookrunners, and Citigroup and RBC Capital Markets, as joint lead managers and joint bookrunners, in connection with the €715 million share capital increase without shareholders' preferential subscription rights and with a priority subscription period for existing shareholders by Tikehau Capital, an asset management and investment group.
  • Interventions

    • June 2, 2020
      COVID-19-Related Transparency and Insider Trading Discussion – A Global Perspective
    • September 12, 2019
      Sustainable Economy: A Global View
    • 15 novembre 2017
      Biotech/Medtech, comment se financer aux États-Unis?
    • November 15, 2017
      Biotech/Medtech, how to raise funds in United States?
    • October 23, 2017
      Seminar for Listed Companies: What You Need to Know About Recent Legal Developments
    • 17 octobre 2017
      Enquêtes internes vs. Enquêtes judiciaires : les liaisons dangereuses ?
    • 13 septembre 2017
      Table ronde Equity Capital Markets (ECM) : Tendances et opérations emblématiques 2017 – Organisée par le Magazine des Affaires, Paris
    • September 13, 2017
      ECM Round Table: Market Trends and Landmark Deals 2017, Organized by the Magazine des Affaires, Paris
    • 20 avril 2017
      Finale de la 3ème édition du Prix Jones Day/ESSEC/Paris II
    • November 9, 2016
      Jones Day Global Life Sciences Conference – 2016 Issues & Trends
    • 7 janvier 2015
      U.S. IPOs : How and Why
    • 13 novembre 2014
      The ABA's 15th Annual "Live from the SEC"
    • October 6, 2014
      BioM-Forum: IPO in the US - a reality
    • 22 septembre 2014
      4ème Dîner-Débat "HEC au Féminin"
    • February 14, 2013
      European Banking – On the Road to Union and Harmonization?
    • Jeudi 17 janvier 2013
      Introduction en bourse aux Etats-Unis et le JOBS Act : enjeux et problématiques
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • June 30, 2011
      Managing Your Risk - Bribery, Corruption and Business Ethics
    • May 23, 2011
      Women in Private Equity: New Frontiers for the MENA Region
    • 23 mai 2011
      Les femmes et le private equity : les nouvelles frontières de la région Moyen-Orient/Afrique du Nord, Séminaire organisé par Venture Catalyst Private Equity Partners avec le soutien de MENA-OCDE Women’s Business Forum, du MENA-OCDE Investment Programme, du Département d’Etat et du Département du Commerce des Etats-Unis
    • 2 mai 2011
      S’informer et échanger pour mieux administrer - Dîner-débat organisé par HEC au Féminin
    • May 2011
      Managing your Risk - Bribery, Corruption and Business Ethics
    • 27 janvier 2011
      Opérations de Spin-off - enjeux et modalités juridiques : La mise en oeuvre des opérations de spin-off, 2ème volet
    • 9 décembre 2010
      Opérations de Spin-off - enjeux et modalités juridiques : Enjeux réglementaires et opportunités, 1er volet
    • July 4, 2007
      Les prises de contrôle rampantes, Association des Juristes de Sciences Po
    • 4 juillet 2007
      Les prises de contrôle rampantes, Association des Juristes de Sciences Po
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    *We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.